U.S. Pharmaceuticals & Biotech Potentially Undervalued Small Caps

TScan Therapeutics

Market Cap: US$60.3m

A clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.

Harvard Bioscience

Market Cap: US$23.7m

Develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.

Traws Pharma

Market Cap: US$11.8m

A clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.

Pharma-Bio Serv

Market Cap: US$11.2m

Operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally.

ImmuCell

Market Cap: US$65.0m

An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.

MariMed

Market Cap: US$26.4m

Engages in cultivation, production, and selling of branded cannabis products in the United States.

Instil Bio

Market Cap: US$57.5m

A clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.

Earth Science Tech

Market Cap: US$35.0m

Together with its subsidies, focuses on health and wellness industry.

Cumberland Pharmaceuticals

Market Cap: US$46.5m

A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.

Dyadic International

Market Cap: US$31.9m

A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.